No Data
No Data
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
Jianshi Technology-B (9877.HK): 6-month clinical data revealed, LuX-Valve Plus showcases global value.
Innovative medical instruments have always been the core focus of medical technology innovation and their development has always been a hot topic in the medical industry. In recent years, many Best-in-class and even pioneering First-in-class medical device projects with leading advantages have emerged in China. At the same time, domestic medical device companies are gradually narrowing the gap with their international peers in terms of R&D cycle, project scale, and technological innovation, and are beginning to shine on the global stage. Jienshi Technology's second-generation guided catheter tricuspid valve replacement system LuX-Valve Plus, developed through independent innovation research and development, is
The 6-month clinical data has shown strong performance, and the global strategy of Health World Technology B (09877) is steadily advancing.
With a wide layout in the high-growth heart valve track, and the upcoming commercial launch of multiple products, the growth potential of Jienshi Technology is already evident.
Director of Technology-B (09877.HK), Pan Fei, increased his shareholding by 2.3328 million shares.
According to the latest equity disclosure information from the Hong Kong Stock Exchange, on June 28, 2024, Healthsec-B (09877.HK) obtained an average price of HKD 3.922 per share and increased its shareholding by 2.3328 million shares, with a total investment of about HKD 9.1492 million. After the increase, the latest number of shares held by Pan Fei, an executive director, is 33.4525 million shares, and the shareholding ratio has increased from 10.03% to 10.78%.
Jenscare Scientific Releases Results of Study on Tricuspid Valve Replacement System in New York, Shanghai
Jenscare Scientific (HKG:9877) released the results of the six-month trial of its LuX-Valve Plus transvascular tricuspid valve replacement system in presentations in New York and Shanghai, according t
Genstox Technology-B (09877.HK): LuX-Valve Plus TRAVEL II six-month clinical follow-up results released.
On July 2nd, Gelonhui announced that recently, the LuX-Valve Plus transcatheter tricuspid valve replacement system, following the six-month clinical follow-up results of the multicenter clinical trial TRAVEL II (Transcatheter tricuspid valve intervention and replacement trial investigation), was officially released at the 2024 American New York Valve Meeting, the 18th Oriental Heart Disease Congress, and the World Heart Disease Congress. TRAVEL II is a prospective, multicenter, single-arm clinical trial designed to evaluate the long-term safety and efficacy of LuX-Valve Plus in patients with severe tricuspid regurgitation.
No Data